Last updated July 12, 2026
Key finding
Postmeal glucose iAUC was 31.4 [23.8-38.9] vs. 38.3 [30.8-45.9]; p = 0.034.
This study evaluated the effects of premeal versus postmeal metformin administration on postmeal glycemic control, finding that premeal administration was more effective.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of premeal versus postmeal metformin administration on postmeal glycemic control, finding that premeal administration was more effective.
Effective management of postmeal blood sugar levels is crucial for individuals with diabetes to prevent complications. This study suggests that timing of metformin administration can significantly influence glycemic control, providing valuable insights for clinical practice and patient education.
Limited generalizability due to specific participant characteristics. Potential confounding factors not fully accounted for. Short duration of the study may not reflect long-term effects.
Published in
Publication details and source links for this paper.
Issaree R, Chatvara A, Khaimook P, La‐Or C, Chutintorn S, Chatchalit R. Premeal immediate-release metformin reduces postmeal glycemic excursions more effectively than postmeal administration. Diabetes, Obesity & Metabolism. 2026;28(7):5779-5786. doi:10.1111/dom.70768
Premeal metformin reduced postmeal glucose iAUC at 0-1h by 6.9 mg/dL.h (p = 0.034).
Premeal metformin reduced CGM glucose iAUC at 0-2h by 15.1 mg/dL.h (p < 0.001).
Premeal metformin reduced CGM glucose iAUC at 0-3h by 17.4 mg/dL.h (p = 0.008).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Metformin and Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours, Continuous glucose monitoring glucose incremental area under the curve at 0-2 hours, Continuous glucose monitoring glucose incremental area under the curve at 0-3 hours, and 4 more.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
7
Evidence pairs
331
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Metformin → Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours
Metformin → Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours
Metformin → Continuous glucose monitoring glucose incremental area under the curve at 0-2 hours
Metformin → Continuous glucose monitoring glucose incremental area under the curve at 0-2 hours
Metformin → Continuous glucose monitoring glucose incremental area under the curve at 0-3 hours
Metformin → Continuous glucose monitoring glucose incremental area under the curve at 0-3 hours
Metformin → Postmeal glucose incremental area under curve (iAUC) at 0-2 hours
Metformin → Postmeal glucose incremental area under curve (iAUC) at 0-2 hours
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Postprandial and OGTT Glucose, Metformin Therapies and Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on Metformin Therapies
Contributes to Metformin Therapies evidence base.
All studies measuring Postprandial and OGTT Glucose
Measures Postprandial and OGTT Glucose as a key outcome.
All studies measuring Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours
Measures Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Metformin Therapies may improve Insulin Resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Insulin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with generally consistent results and a positive effect signal.
Limitations
Metformin Therapies appears to improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Limitations
Metformin appears to improve Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Continuous glucose monitoring glucose incremental area under the curve at 0-1 hours
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Metformin appears to improve Continuous glucose monitoring glucose incremental area under the curve at 0-2 hours.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Continuous glucose monitoring glucose incremental area under the curve at 0-2 hours
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
